Drug intelligence / Profile preview

GKL-006RTU

Development stage: Phase 2
Lead developer: Geneplus-Beijing Co. Ltd.
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

GKL-006RTU is a cell therapy product consisting of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) developed by Beijing Gene-Eden Biotechnology (北京基因启明生物科技有限公司). It is currently being evaluated in Phase I/II clinical trials for the treatment of moderate to severe acute respiratory distress syndrome (ARDS), particularly cases of infectious etiology. Mesenchymal stem cells are known for their immunomodulatory, anti-inflammatory, and tissue-repair properties, which are hypothesized to mitigate the cytokine storm and lung injury associated with ARDS. The "RTU" suffix likely indicates a "Ready-To-Use" formulation designed for immediate clinical administration.

Other names: GKL-006RTU injectionGKL006RTU injectionGKL 006RTU injection

Beyond the preview

Go deeper on GKL-006RTU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKL-006RTU.

Explore the full profile